BioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or Schizophrenia

May 25, 2023 by Leave a Comment

Last Updated on May 25, 2023 by

[#item_full_content]

Spread the word

You must log in to post a comment.

We provide a balanced view on small cap biotech equities

Address : Santa Fe, New Mexico.

Generated by Feedzy

%d bloggers like this:

Reader Interactions